Abstract
Bipolar disorder (BD) is a severe psychiatric illness characterized by recurrent manic and depressive episodes, without a characteristic neuropathology or clear etiology. Drugs effective in BD target many key signaling pathways in animal and cell studies. However, their mode of action in the BD brain remains elusive. In the rat brain, some of the mood stabilizers effective in treating mania (lithium, carbamazepine, valproate) or depression (lamotrigine) in BD are reported to decrease transcription of cytosolic phospholipase A2 and cyclooxygenase-2 and to reduce levels of AP-2 and NF-κB, transcription factors of the two enzymes. The anti-manic drugs also decrease arachidonic acid (AA) turnover in brain phospholipids when given chronically to rats. Thus, drugs effective in BD commonly target AA cascade kinetics as well as AA cascade enzymes and their transcription factors in the rat brain. These studies suggest that of BD is associated with increased AA signaling in the brain. Developing therapeutic agents that suppress brain AA signaling could lead to additional treatments for BD. In this review, we discuss the mechanisms of action of mood stabilizers and the effects of docosahexaenoic acid on AA cascade enzymes in relation to BD.
Keywords: Bipolar disorder, cPLA2, sPLA2, COX-2, AP-2, NF-κB, arachidonic acid, mood stabilizers
Current Molecular Pharmacology
Title: Mood-Stabilizers Target the Brain Arachidonic Acid Cascade
Volume: 2
Author(s): Jagadeesh S. Rao and Stanley I. Rapoport
Affiliation:
Keywords: Bipolar disorder, cPLA2, sPLA2, COX-2, AP-2, NF-κB, arachidonic acid, mood stabilizers
Abstract: Bipolar disorder (BD) is a severe psychiatric illness characterized by recurrent manic and depressive episodes, without a characteristic neuropathology or clear etiology. Drugs effective in BD target many key signaling pathways in animal and cell studies. However, their mode of action in the BD brain remains elusive. In the rat brain, some of the mood stabilizers effective in treating mania (lithium, carbamazepine, valproate) or depression (lamotrigine) in BD are reported to decrease transcription of cytosolic phospholipase A2 and cyclooxygenase-2 and to reduce levels of AP-2 and NF-κB, transcription factors of the two enzymes. The anti-manic drugs also decrease arachidonic acid (AA) turnover in brain phospholipids when given chronically to rats. Thus, drugs effective in BD commonly target AA cascade kinetics as well as AA cascade enzymes and their transcription factors in the rat brain. These studies suggest that of BD is associated with increased AA signaling in the brain. Developing therapeutic agents that suppress brain AA signaling could lead to additional treatments for BD. In this review, we discuss the mechanisms of action of mood stabilizers and the effects of docosahexaenoic acid on AA cascade enzymes in relation to BD.
Export Options
About this article
Cite this article as:
Rao S. Jagadeesh and Rapoport I. Stanley, Mood-Stabilizers Target the Brain Arachidonic Acid Cascade, Current Molecular Pharmacology 2009; 2 (2) . https://dx.doi.org/10.2174/1874467210902020207
DOI https://dx.doi.org/10.2174/1874467210902020207 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Liquid Chromatography Coupled to Electrochemical Detection and Mass Spectrometry for the Determination of Phenolic Compounds in Food and Beverages
Current Analytical Chemistry Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Novel Hybrid Molecules on the Basis of Steroids and (5Z,9Z)-Tetradeca-5,9-dienoic Acid: Synthesis, Anti-Cancer Studies and Human Topoisomerase I Inhibitory Activity
Anti-Cancer Agents in Medicinal Chemistry <i>In vitro</i> and <i>In vivo</i> Toxicity Assessment of Metallic Nanoparticulate Systems for Skin Targeting
Current Nanotoxicity and Prevention (Discontinued) Qualitative and Quantitative Analysis of Phosphoproteomic Experimental Workflow Based on Phosphoprotein Enrichment Strategy and Two- Dimensional Difference Gel Electrophoresis (2D-DIGE) Techniques
Current Proteomics Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design The Challenges Involved in Modeling Toxicity Data In Silico: A Review
Current Pharmaceutical Design Cannabis and Psychosis: A Systematic Review of Genetic Studies
Current Psychiatry Reviews Quantitative Structure-Activity Relationships for Commercially Available Inhibitors of COX-2
Medicinal Chemistry Differential Expression of miR-20a and miR-145 in Colorectal Tumors as Potential Location-specific miRNAs
MicroRNA Evaluation of Cytotoxic and Tyrosinase Inhibitory Activities of 2-phenoxy(thiomethyl) pyridotriazolopyrimidines: In Vitro and Molecular Docking Studies
Anti-Cancer Agents in Medicinal Chemistry Deep Convolutional Neural Networks for Predicting Hydroxyproline in Proteins
Current Bioinformatics Synthesis and Biological Evaluation of Sulfonilamidothienopyrimidinone Derivatives as Novel Anti-inflammatory Agents
Medicinal Chemistry Determination of Some Kinetic and Characteristic Properties of Glutathione S-transferase from Bovine Erythrocytes
Protein & Peptide Letters Nociceptin/Orphanin FQ Peptide Receptor as a Therapeutic Target for Obesity
Mini-Reviews in Medicinal Chemistry Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production
Current Drug Delivery Biological Network Derivation by Positive Unlabeled Learning Algorithms
Current Bioinformatics